

Elisabeth G E De Vries

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6678143/publications.pdf>

Version: 2024-02-01

452
papers

38,829
citations

4960

84
h-index

3650

180
g-index

454
all docs

454
docs citations

454
times ranked

45479
citing authors

#	ARTICLE	IF	CITATIONS
1	Effect of radiotherapy after breast-conserving surgery on 10-year recurrence and 15-year breast cancer death: meta-analysis of individual patient data for 10 801 women in 17 randomised trials. Lancet, The, 2011, 378, 1707-1716.	13.7	3,080
2	Everolimus for Advanced Pancreatic Neuroendocrine Tumors. New England Journal of Medicine, 2011, 364, 514-523.	27.0	2,547
3	Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of randomised trials. Lancet, The, 2011, 378, 771-784.	13.7	2,495
4	Effect of radiotherapy after mastectomy and axillary surgery on 10-year recurrence and 20-year breast cancer mortality: meta-analysis of individual patient data for 8135 women in 22 randomised trials. Lancet, The, 2014, 383, 2127-2135.	13.7	1,701
5	iRECIST: guidelines for response criteria for use in trials testing immunotherapeutics. Lancet Oncology, The, 2017, 18, e143-e152.	10.7	1,612
6	RECIST 1.1 Update and clarification: From the RECIST committee. European Journal of Cancer, 2016, 62, 132-137.	2.8	1,143
7	20-Year Risks of Breast-Cancer Recurrence after Stopping Endocrine Therapy at 5 Years. New England Journal of Medicine, 2017, 377, 1836-1846.	27.0	1,052
8	Response assessment criteria for brain metastases: proposal from the RANO group. Lancet Oncology, The, 2015, 16, e270-e278.	10.7	711
9	A standardised, generic, validated approach to stratify the magnitude of clinical benefit that can be anticipated from anti-cancer therapies: the European Society for Medical Oncology Magnitude of Clinical Benefit Scale (ESMO-MCBS). Annals of Oncology, 2015, 26, 1547-1573.	1.2	635
10	Evidence Based Selection of Housekeeping Genes. PLoS ONE, 2007, 2, e898.	2.5	617
11	A review on CXCR4/CXCL12 axis in oncology: No place to hide. European Journal of Cancer, 2013, 49, 219-230.	2.8	526
12	⁸⁹ Zr-atezolizumab imaging as a non-invasive approach to assess clinical response to PD-L1 blockade in cancer. Nature Medicine, 2018, 24, 1852-1858.	30.7	468
13	ESMO-Magnitude of Clinical Benefit Scale version 1.1. Annals of Oncology, 2017, 28, 2340-2366.	1.2	451
14	Metformin: Taking away the candy for cancer?. European Journal of Cancer, 2010, 46, 2369-2380.	2.8	345
15	Trastuzumab duocarmazine in locally advanced and metastatic solid tumours and HER2-expressing breast cancer: a phase 1 dose-escalation and dose-expansion study. Lancet Oncology, The, 2019, 20, 1124-1135.	10.7	339
16	Gene expression analysis identifies global gene dosage sensitivity in cancer. Nature Genetics, 2015, 47, 115-125.	21.4	313
17	Development and Characterization of Clinical-Grade ⁸⁹ Zr-Trastuzumab for HER2/neu ImmunoPET Imaging. Journal of Nuclear Medicine, 2009, 50, 974-981.	5.0	305
18	Tumor-associated macrophages in breast cancer: Innocent bystander or important player?. Cancer Treatment Reviews, 2018, 70, 178-189.	7.7	305

#	ARTICLE	IF	CITATIONS
19	Immuno-PET: A Navigator in Monoclonal Antibody Development and Applications. <i>Oncologist</i> , 2007, 12, 1379-1389.	3.7	304
20	Relevance of Tumor-Infiltrating Immune Cell Composition and Functionality for Disease Outcome in Breast Cancer. <i>Journal of the National Cancer Institute</i> , 2017, 109, djw192.	6.3	296
21	Molecular and Clinical Characteristics of MSH6 Variants: An Analysis of 25 Index Carriers of a Germline Variant. <i>American Journal of Human Genetics</i> , 2002, 70, 26-37.	6.2	271
22	Indium-111 ⁺ Labeled Trastuzumab Scintigraphy in Patients With Human Epidermal Growth Factor Receptor 2 ⁺ Positive Metastatic Breast Cancer. <i>Journal of Clinical Oncology</i> , 2006, 24, 2276-2282.	1.6	270
23	Molecular imaging as a tool to investigate heterogeneity of advanced HER2-positive breast cancer and to predict patient outcome under trastuzumab emtansine (T-DM1): the ZEPHIR trial. <i>Annals of Oncology</i> , 2016, 27, 619-624.	1.2	269
24	High-Dose Chemotherapy with Hematopoietic Stem-Cell Rescue for High-Risk Breast Cancer. <i>New England Journal of Medicine</i> , 2003, 349, 7-16.	27.0	240
25	Improved Staging of Patients With Carcinoid and Islet Cell Tumors With ¹⁸ F-Dihydroxy-Phenyl-Alanine and ¹¹ C-5-Hydroxy-Tryptophan Positron Emission Tomography. <i>Journal of Clinical Oncology</i> , 2008, 26, 1489-1495.	1.6	240
26	Rectal and colon cancer: Not just a different anatomic site. <i>Cancer Treatment Reviews</i> , 2015, 41, 671-679.	7.7	239
27	Cardiovascular toxicity caused by cancer treatment: strategies for early detection. <i>Lancet Oncology</i> , 2009, 10, 391-399.	10.7	235
28	Staging of carcinoid tumours with 18F-DOPA PET: a prospective, diagnostic accuracy study. <i>Lancet Oncology</i> , 2006, 7, 728-734.	10.7	234
29	ATP ⁺ and glutathione ⁺ dependent transport of chemotherapeutic drugs by the multidrug resistance protein MRP1. <i>British Journal of Pharmacology</i> , 1999, 126, 681-688.	5.4	224
30	Tumor-Specific Uptake of Fluorescent Bevacizumab ⁺ IRDye800CW Microdosing in Patients with Primary Breast Cancer: A Phase I Feasibility Study. <i>Clinical Cancer Research</i> , 2017, 23, 2730-2741.	7.0	212
31	RECIST 1.1 ⁺ Standardisation and disease-specific adaptations: Perspectives from the RECIST Working Group. <i>European Journal of Cancer</i> , 2016, 62, 138-145.	2.8	211
32	Everolimus for the Treatment of Advanced Pancreatic Neuroendocrine Tumors: Overall Survival and Circulating Biomarkers From the Randomized, Phase III RADIANT-3 Study. <i>Journal of Clinical Oncology</i> , 2016, 34, 3906-3913.	1.6	206
33	A review of bispecific antibodies and antibody constructs in oncology and clinical challenges. , 2019, 201, 103-119.		194
34	Receptor conversion in distant breast cancer metastases. <i>Breast Cancer Research</i> , 2010, 12, R75.	5.0	189
35	Intraoperative Near-Infrared Fluorescence Tumor Imaging with Vascular Endothelial Growth Factor and Human Epidermal Growth Factor Receptor 2 Targeting Antibodies. <i>Journal of Nuclear Medicine</i> , 2011, 52, 1778-1785.	5.0	186
36	Risk of New Primary Nonbreast Cancers After Breast Cancer Treatment: A Dutch Population-Based Study. <i>Journal of Clinical Oncology</i> , 2008, 26, 1239-1246.	1.6	181

#	ARTICLE	IF	CITATIONS
37	CXCR4 Inhibition with AMD3100 Sensitizes Prostate Cancer to Docetaxel Chemotherapy. <i>Neoplasia</i> , 2012, 14, 709-718.	5.3	176
38	Translating Pharmacogenomics: Challenges on the Road to the Clinic. <i>PLoS Medicine</i> , 2007, 4, e209.	8.4	174
39	PET imaging of oestrogen receptors in patients with breast cancer. <i>Lancet Oncology</i> , The, 2013, 14, e465-e475.	10.7	173
40	Measuring Residual Estrogen Receptor Availability during Fulvestrant Therapy in Patients with Metastatic Breast Cancer. <i>Cancer Discovery</i> , 2015, 5, 72-81.	9.4	168
41	Angiotensin IIâ€“Receptor Inhibition With Candesartan to Prevent Trastuzumab-Related Cardiotoxic Effects in Patients With Early Breast Cancer. <i>JAMA Oncology</i> , 2016, 2, 1030.	7.1	160
42	An oncological view on the bloodâ€“testis barrier. <i>Lancet Oncology</i> , The, 2002, 3, 357-363.	10.7	158
43	Cross-cohort gut microbiome associations with immune checkpoint inhibitor response in advanced melanoma. <i>Nature Medicine</i> , 2022, 28, 535-544.	30.7	158
44	Survival-Related Profile, Pathways, and Transcription Factors in Ovarian Cancer. <i>PLoS Medicine</i> , 2009, 6, e1000024.	8.4	156
45	6-[F-18]Fluoro- ¹ -Dihydroxyphenylalanine Positron Emission Tomography Is Superior to Conventional Imaging with 123I-Metaiodobenzylguanidine Scintigraphy, Computer Tomography, and Magnetic Resonance Imaging in Localizing Tumors Causing Catecholamine Excess. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2009, 94, 3922-3930.	3.6	153
46	An aCGH classifier derived from BRCA1-mutated breast cancer and benefit of high-dose platinum-based chemotherapy in HER2-negative breast cancer patients. <i>Annals of Oncology</i> , 2011, 22, 1561-1570.	1.2	150
47	Lessons from TRAIL-resistance mechanisms in colorectal cancer cells: paving the road to patient-tailored therapy. <i>Drug Resistance Updates</i> , 2004, 7, 345-358.	14.4	146
48	⁸⁹ Zr-Bevacizumab PET Imaging in Primary Breast Cancer. <i>Journal of Nuclear Medicine</i> , 2013, 54, 1014-1018.	5.0	141
49	Preclinical characterisation of ¹¹¹ In-DTPA-trastuzumab. <i>British Journal of Pharmacology</i> , 2004, 143, 99-106.	5.4	140
50	PET Imaging of Estrogen Receptors as a Diagnostic Tool for Breast Cancer Patients Presenting with a Clinical Dilemma. <i>Journal of Nuclear Medicine</i> , 2012, 53, 182-190.	5.0	136
51	Molecular imaging in neuroendocrine tumors: Molecular uptake mechanisms and clinical results. <i>Critical Reviews in Oncology/Hematology</i> , 2009, 71, 199-213.	4.4	135
52	COVID-19 vaccines in patients with cancer: immunogenicity, efficacy and safety. <i>Nature Reviews Clinical Oncology</i> , 2022, 19, 385-401.	27.6	135
53	Plasma Free Metanephrine Measurement Using Automated Online Solid-Phase Extraction HPLCâ€“Tandem Mass Spectrometry. <i>Clinical Chemistry</i> , 2007, 53, 1684-1693.	3.2	132
54	Dietary Influences on Plasma and Urinary Metanephrines: Implications for Diagnosis of Catecholamine-Producing Tumors. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2009, 94, 2841-2849.	3.6	131

#	ARTICLE	IF	CITATIONS
55	Discriminating Capacity of Indole Markers in the Diagnosis of Carcinoid Tumors. <i>Clinical Chemistry</i> , 2000, 46, 1588-1596.	3.2	120
56	Toward New Strategies to Select Young Endometrial Cancer Patients for Mismatch Repair Gene Mutation Analysis. <i>Journal of Clinical Oncology</i> , 2003, 21, 4364-4370.	1.6	120
57	Fas receptor-mediated apoptosis: a clinical application?. <i>Journal of Pathology</i> , 2002, 196, 125-134.	4.5	118
58	Expression of TRAIL (TNF-related apoptosis-inducing ligand) and its receptors in normal colonic mucosa, adenomas, and carcinomas. <i>Journal of Pathology</i> , 2003, 200, 327-335.	4.5	118
59	mRNA-1273 COVID-19 vaccination in patients receiving chemotherapy, immunotherapy, or chemoimmunotherapy for solid tumours: a prospective, multicentre, non-inferiority trial. <i>Lancet Oncology</i> , The, 2021, 22, 1681-1691.	10.7	118
60	Expression and activity of breast cancer resistance protein (BCRP) in de novo and relapsed acute myeloid leukemia. <i>Blood</i> , 2002, 99, 3763-3770.	1.4	116
61	¹⁸ F-Dihydroxyphenylalanine PET in Patients with Biochemical Evidence of Medullary Thyroid Cancer: Relation to Tumor Differentiation. <i>Journal of Nuclear Medicine</i> , 2008, 49, 524-531.	5.0	116
62	Involvement of the TGF- β 2 and β 2-Catenin Pathways in Pelvic Lymph Node Metastasis in Early-Stage Cervical Cancer. <i>Clinical Cancer Research</i> , 2011, 17, 1317-1330.	7.0	113
63	Clinical relevance of transforming growth factor α , epidermal growth factor receptor, p53, and Ki67 in colorectal liver metastases and corresponding primary tumors. <i>Hepatology</i> , 1998, 28, 971-979.	7.3	112
64	⁸⁹ Zr-Bevacizumab PET of Early Antiangiogenic Tumor Response to Treatment with HSP90 Inhibitor NVP-AUY922. <i>Journal of Nuclear Medicine</i> , 2010, 51, 761-767.	5.0	109
65	Forced activation of Cdk1 via wee1 inhibition impairs homologous recombination. <i>Oncogene</i> , 2013, 32, 3001-3008.	5.9	108
66	Encouraging AwaRe-ness and discouraging inappropriate antibiotic use—the new 2019 Essential Medicines List becomes a global antibiotic stewardship tool. <i>Lancet Infectious Diseases</i> , The, 2019, 19, 1278-1280.	9.1	106
67	VEGF-PET Imaging Is a Noninvasive Biomarker Showing Differential Changes in the Tumor during Sunitinib Treatment. <i>Cancer Research</i> , 2011, 71, 143-153.	0.9	105
68	⁸⁹ Zr-trastuzumab and ⁸⁹ Zr-bevacizumab PET to Evaluate the Effect of the HSP90 Inhibitor NVP-AUY922 in Metastatic Breast Cancer Patients. <i>Clinical Cancer Research</i> , 2014, 20, 3945-3954.	7.0	105
69	Expression of Multidrug Resistance-Associated Proteins Predicts Prognosis in Childhood and Adult Acute Lymphoblastic Leukemia. <i>Clinical Cancer Research</i> , 2005, 11, 8661-8668.	7.0	103
70	Bevacizumab-Induced Normalization of Blood Vessels in Tumors Hampers Antibody Uptake. <i>Cancer Research</i> , 2013, 73, 3347-3355.	0.9	103
71	Comparative Assessment of Clinical Benefit Using the ESMO-Magnitude of Clinical Benefit Scale Version 1.1 and the ASCO Value Framework Net Health Benefit Score. <i>Journal of Clinical Oncology</i> , 2019, 37, 336-349.	1.6	101
72	Mapatumumab, a Fully Human Agonistic Monoclonal Antibody That Targets TRAIL-R1, in Combination with Gemcitabine and Cisplatin: a Phase I Study. <i>Clinical Cancer Research</i> , 2009, 15, 5584-5590.	7.0	100

#	ARTICLE	IF	CITATIONS
73	⁸⁹ Zr-Bevacizumab PET Visualizes Heterogeneous Tracer Accumulation in Tumor Lesions of Renal Cell Carcinoma Patients and Differential Effects of Antiangiogenic Treatment. Journal of Nuclear Medicine, 2015, 56, 63-69.	5.0	100
74	Expression of TRAIL and TRAIL death receptors in stage III non-small cell lung cancer tumors. Clinical Cancer Research, 2003, 9, 3397-405.	7.0	100
75	The impact of adjuvant therapy on contralateral breast cancer risk and the prognostic significance of contralateral breast cancer: a population based study in the Netherlands. Breast Cancer Research and Treatment, 2008, 110, 189-197.	2.5	97
76	Modest effect of p53, EGFR and HER-2/neu on prognosis in epithelial ovarian cancer: a meta-analysis. British Journal of Cancer, 2009, 101, 149-159.	6.4	97
77	Phase I Safety, Pharmacokinetic, and Pharmacodynamic Study of the Thrombospondin-1 Mimetic Angiogenesis Inhibitor ABT-510 in Patients With Advanced Cancer. Journal of Clinical Oncology, 2005, 23, 5188-5197.	1.6	96
78	Playing the DISC: Turning on TRAIL death receptor-mediated apoptosis in cancer. Biochimica Et Biophysica Acta: Reviews on Cancer, 2010, 1805, 123-140.	7.4	96
79	Tryptophan as a Link between Psychopathology and Somatic States. Psychosomatic Medicine, 2003, 65, 665-671.	2.0	93
80	⁸⁹ Zr-trastuzumab PET visualises HER2 downregulation by the HSP90 inhibitor NVP-AUY922 in a human tumour xenograft. European Journal of Cancer, 2010, 46, 678-684.	2.8	93
81	Antibody Positron Emission Tomography Imaging in Anticancer Drug Development. Journal of Clinical Oncology, 2015, 33, 1491-1504.	1.6	93
82	The (patho)physiological functions of the MRP family. Drug Resistance Updates, 2000, 3, 289-302.	14.4	91
83	Plasma tryptophan, kynurenine and 3-hydroxykynurenine measurement using automated on-line solid-phase extraction HPLC-tandem mass spectrometry. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 2009, 877, 603-609.	2.3	91
84	High-Dose Chemotherapy With Autologous Stem-Cell Support As Adjuvant Therapy in Breast Cancer: Overview of 15 Randomized Trials. Journal of Clinical Oncology, 2011, 29, 3214-3223.	1.6	89
85	Clinical trial design for systemic agents in patients with brain metastases from solid tumours: a guideline by the Response Assessment in Neuro-Oncology Brain Metastases working group. Lancet Oncology, The, 2018, 19, e20-e32.	10.7	87
86	Profiling of Tryptophan-related Plasma Indoles in Patients with Carcinoid Tumors by Automated, On-Line, Solid-Phase Extraction and HPLC with Fluorescence Detection. Clinical Chemistry, 2001, 47, 1811-1820.	3.2	86
87	Fatigue and Relating Factors in High-Risk Breast Cancer Patients Treated With Adjuvant Standard or High-Dose Chemotherapy: A Longitudinal Study. Journal of Clinical Oncology, 2005, 23, 8296-8304.	1.6	86
88	Genomic patterns resembling BRCA1- and BRCA2-mutated breast cancers predict benefit of intensified carboplatin-based chemotherapy. Breast Cancer Research, 2014, 16, R47.	5.0	86
89	VEGF pathway targeting agents, vessel normalization and tumor drug uptake: from bench to bedside. Oncotarget, 2016, 7, 21247-21258.	1.8	86
90	ABC transporter expression in hematopoietic stem cells and the role in AML drug resistance. Critical Reviews in Oncology/Hematology, 2007, 62, 214-226.	4.4	85

#	ARTICLE	IF	CITATIONS
91	Phase I Study of DMOT4039A, an Antibody-Drug Conjugate Targeting Mesothelin, in Patients with Unresectable Pancreatic or Platinum-Resistant Ovarian Cancer. <i>Molecular Cancer Therapeutics</i> , 2016, 15, 439-447.	4.1	85
92	Theranostics Using Antibodies and Antibody-Related Therapeutics. <i>Journal of Nuclear Medicine</i> , 2017, 58, 83S-90S.	5.0	85
93	ESMO / ASCO Recommendations for a Global Curriculum in Medical Oncology Edition 2016. <i>ESMO Open</i> , 2016, 1, e000097.	4.5	82
94	Better Yield of ¹⁸ F-Fluorodeoxyglucose-Positron Emission Tomography in Patients with Metastatic Differentiated Thyroid Carcinoma during Thyrotropin Stimulation. <i>Thyroid</i> , 2002, 12, 381-387.	4.5	81
95	Internet-based support programs to alleviate psychosocial and physical symptoms in cancer patients: A literature analysis. <i>Critical Reviews in Oncology/Hematology</i> , 2015, 95, 26-37.	4.4	81
96	Quantitative assessment of P-glycoprotein function in the rat blood-brain barrier by distribution volume of [¹¹ C]verapamil measured with PET. <i>NeuroImage</i> , 2003, 20, 1775-1782.	4.2	80
97	ATR inhibition preferentially targets homologous recombination-deficient tumor cells. <i>Oncogene</i> , 2015, 34, 3474-3481.	5.9	80
98	The ErbB signalling pathway: protein expression and prognostic value in epithelial ovarian cancer. <i>British Journal of Cancer</i> , 2008, 99, 341-349.	6.4	78
99	TGF- β 2 Antibody Uptake in Recurrent High-Grade Glioma Imaged with ⁸⁹ Zr-Fresolimumab PET. <i>Journal of Nuclear Medicine</i> , 2015, 56, 1310-1314.	5.0	78
100	RECIST - learning from the past to build the future. <i>Nature Reviews Clinical Oncology</i> , 2017, 14, 187-192.	27.6	78
101	Influence of functional polymorphisms of the gene on vincristine pharmacokinetics in childhood acute lymphoblastic leukemia. <i>Clinical Pharmacology and Therapeutics</i> , 2004, 76, 220-229.	4.7	77
102	Clinical Evaluation of M30 and M65 ELISA Cell Death Assays as Circulating Biomarkers in a Drug-Sensitive Tumor, Testicular Cancer. <i>Neoplasia</i> , 2008, 10, 1041-1048.	5.3	77
103	Rif1 Is Required for Resolution of Ultrafine DNA Bridges in Anaphase to Ensure Genomic Stability. <i>Developmental Cell</i> , 2015, 34, 466-474.	7.0	74
104	ImmunopET with Anti-Mesothelin Antibody in Patients with Pancreatic and Ovarian Cancer before Anti-Mesothelin Antibody-Drug Conjugate Treatment. <i>Clinical Cancer Research</i> , 2016, 22, 1642-1652.	7.0	74
105	The attractive Achilles heel of germ cell tumours: an inherent sensitivity to apoptosis-inducing stimuli. <i>Journal of Pathology</i> , 2003, 200, 137-148.	4.5	71
106	TAMOXIFEN TREATMENT AND GYNECOLOGIC SIDE EFFECTS. <i>Obstetrics and Gynecology</i> , 2001, 97, 855-866.	2.4	69
107	EUS is superior for detection of pancreatic lesions compared with standard imaging in patients with multiple endocrine neoplasia type 1. <i>Gastrointestinal Endoscopy</i> , 2015, 81, 159-167.e2.	1.0	69
108	Access to cancer medicines deemed essential by oncologists in 82 countries: an international, cross-sectional survey. <i>Lancet Oncology</i> , The, 2021, 22, 1367-1377.	10.7	69

#	ARTICLE	IF	CITATIONS
109	Translating TRAIL-receptor targeting agents to the clinic. <i>Cancer Letters</i> , 2013, 332, 194-201.	7.2	67
110	Evolution in sentinel lymph node biopsy in breast cancer. <i>Critical Reviews in Oncology/Hematology</i> , 2018, 123, 83-94.	4.4	67
111	Current status and future developments of LC-MS/MS in clinical chemistry for quantification of biogenic amines. <i>Clinical Biochemistry</i> , 2011, 44, 95-103.	1.9	66
112	Successful long-term control of idiopathic hypereosinophilic syndrome with etoposide. <i>Cancer</i> , 1991, 67, 2826-2827.	4.1	65
113	<scp>APC</scp></scp>^C</sup></sup>dh1</sup> controls Ct^{IP} stability during the cell cycle and in response to ^{DNA} damage. <i>EMBO Journal</i> , 2014, 33, 2860-2879.	7.8	65
114	Consideration of breast cancer subtype in targeting the androgen receptor. , 2019, 200, 135-147.		65
115	Dutch Oncology COVID-19 consortium: Outcome of COVID-19 in patients with cancer in a nationwide cohort study. <i>European Journal of Cancer</i> , 2020, 141, 171-184.	2.8	65
116	JM216-, JM118-, and cisplatin-induced cytotoxicity in relation to platinum-DNA adduct formation, glutathione levels and p53 status in human tumour cell lines with different sensitivities to cisplatin. <i>Biochemical Pharmacology</i> , 2002, 63, 1989-1996.	4.4	64
117	Prognosis in childhood and adult acute lymphoblastic leukaemia: a question of maturation?. <i>Cancer Treatment Reviews</i> , 2004, 30, 37-51.	7.7	64
118	Hot flushes in breast cancer patients. <i>Critical Reviews in Oncology/Hematology</i> , 2006, 57, 63-77.	4.4	64
119	Automated mass spectrometric analysis of urinary and plasma serotonin. <i>Analytical and Bioanalytical Chemistry</i> , 2010, 396, 2609-2616.	3.7	64
120	Profiling Studies in Ovarian Cancer: A Review. <i>Oncologist</i> , 2007, 12, 960-966.	3.7	63
121	The influence of endocrine treatments for breast cancer on health-related quality of life. <i>Cancer Treatment Reviews</i> , 2008, 34, 640-655.	7.7	63
122	Everolimus Induces Rapid Plasma Glucose Normalization in Insulinoma Patients by Effects on Tumor As Well As Normal Tissues. <i>Oncologist</i> , 2011, 16, 783-787.	3.7	62
123	Long-term exposure to circulating platinum is associated with late effects of treatment in testicular cancer survivors. <i>Annals of Oncology</i> , 2015, 26, 2305-2310.	1.2	61
124	Bone metastases in carcinoid tumors: clinical features, imaging characteristics, and markers of bone metabolism. <i>Journal of Nuclear Medicine</i> , 2003, 44, 184-91.	5.0	60
125	In vivo imaging of hepatobiliary transport function mediated by multidrug resistance associated protein and P-glycoprotein. <i>Cancer Chemotherapy and Pharmacology</i> , 2004, 54, 131-138.	2.3	58
126	Venlafaxine versus clonidine for the treatment of hot flashes in breast cancer patients: a double-blind, randomized cross-over study. <i>Breast Cancer Research and Treatment</i> , 2009, 115, 573-580.	2.5	58

#	ARTICLE	IF	CITATIONS
127	Regulators of homologous recombination repair as novel targets for cancer treatment. <i>Frontiers in Genetics</i> , 2015, 6, 96.	2.3	58
128	Preoperative Serum Squamous Cell Carcinoma Antigen Levels in Clinical Decision Making for Patients With Early-Stage Cervical Cancer. <i>Journal of Clinical Oncology</i> , 2005, 23, 1455-1462.	1.6	57
129	Diminished expression of multidrug resistance-associated protein 1 (MRP1) in bronchial epithelium of COPD patients. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2006, 449, 682-688.	2.8	57
130	Automated mass spectrometric analysis of urinary free catecholamines using on-line solid phase extraction. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2010, 878, 1506-1512.	2.3	57
131	Dopamine and serotonin regulate tumor behavior by affecting angiogenesis. <i>Drug Resistance Updates</i> , 2014, 17, 96-104.	14.4	57
132	Transport of glutathione conjugates into secretory vesicles is mediated by the multidrug-resistance protein 1. , 1998, 76, 55-62.		56
133	Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand Pathway and Its Therapeutic Implications. <i>Clinical Cancer Research</i> , 2006, 12, 2390-2393.	7.0	56
134	Measurement of Tumor VEGF-A Levels with ⁸⁹ Zr-Bevacizumab PET as an Early Biomarker for the Antiangiogenic Effect of Everolimus Treatment in an Ovarian Cancer Xenograft Model. <i>Clinical Cancer Research</i> , 2012, 18, 6306-6314.	7.0	56
135	Everolimus Reduces ⁸⁹ Zr-Bevacizumab Tumor Uptake in Patients with Neuroendocrine Tumors. <i>Journal of Nuclear Medicine</i> , 2014, 55, 1087-1092.	5.0	56
136	Integrating molecular nuclear imaging in clinical research to improve anticancer therapy. <i>Nature Reviews Clinical Oncology</i> , 2019, 16, 241-255.	27.6	56
137	Role of Chemokines and Their Receptors in Cancer. <i>Current Pharmaceutical Design</i> , 2009, 15, 3396-3416.	1.9	55
138	HER3, serious partner in crime. , 2014, 143, 1-11.		55
139	Manipulation of [11C]-5-Hydroxytryptophan and 6-[18F]Fluoro-3,4-Dihydroxy-L-Phenylalanine Accumulation in Neuroendocrine Tumor Cells. <i>Cancer Research</i> , 2008, 68, 7183-7190.	0.9	54
140	Systolic and diastolic dysfunction in long-term adult survivors of childhood cancer. <i>European Journal of Cancer</i> , 2011, 47, 2453-2462.	2.8	54
141	Breaking the DNA damage response to improve cervical cancer treatment. <i>Cancer Treatment Reviews</i> , 2016, 42, 30-40.	7.7	54
142	Testicular germ cell tumours: The paradigm of chemo-sensitive solid tumours. <i>International Journal of Biochemistry and Cell Biology</i> , 2005, 37, 2437-2456.	2.8	53
143	Lesion detection by [89Zr]Zr-DFO-girentuximab and [18F]FDG-PET/CT in patients with newly diagnosed metastatic renal cell carcinoma. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2019, 46, 1931-1939.	6.4	53
144	RECIST 1.1 for Response Evaluation Apply Not Only to Chemotherapy-Treated Patients But Also to Targeted Cancer Agents: A Pooled Database Analysis. <i>Journal of Clinical Oncology</i> , 2019, 37, 1102-1110.	1.6	53

#	ARTICLE	IF	CITATIONS
145	COVID-19 vaccination: the VOICE for patients with cancer. <i>Nature Medicine</i> , 2021, 27, 568-569.	30.7	53
146	Transcriptional effects of copy number alterations in a large set of human cancers. <i>Nature Communications</i> , 2020, 11, 715.	12.8	53
147	Catecholamine-Synthesizing Enzymes in Carcinoid Tumors and Pheochromocytomas. <i>Clinical Chemistry</i> , 2003, 49, 586-593.	3.2	52
148	Proteasome inhibitor MG132 sensitizes HPV-positive human cervical cancer cells to rhTRAIL-induced apoptosis. <i>International Journal of Cancer</i> , 2006, 118, 1892-1900.	5.1	52
149	Endothelial Damage in Long-Term Survivors of Childhood Cancer. <i>Journal of Clinical Oncology</i> , 2013, 31, 3906-3913.	1.6	52
150	Comparison of the kinetics of active efflux of ^{99m} Tc-MIBI in cells with P-glycoprotein-mediated and multidrug-resistance protein-associated multidrug-resistance phenotypes. <i>FEBS Journal</i> , 1998, 252, 140-146.	0.2	51
151	Serum HER2 levels are increased in patients with chronic heart failure. <i>European Journal of Heart Failure</i> , 2007, 9, 173-177.	7.1	51
152	VEGF-SPECT with ¹¹¹ In-bevacizumab in stage III/IV melanoma patients. <i>European Journal of Cancer</i> , 2011, 47, 1595-1602.	2.8	51
153	PET with the ⁸⁹ Zr-Labeled Transforming Growth Factor- β 2 Antibody Fresolimumab in Tumor Models. <i>Journal of Nuclear Medicine</i> , 2011, 52, 2001-2008.	5.0	51
154	⁸⁹ Zr-Lumretuzumab PET Imaging before and during HER3 Antibody Lumretuzumab Treatment in Patients with Solid Tumors. <i>Clinical Cancer Research</i> , 2017, 23, 6128-6137.	7.0	51
155	⁸⁹ Zr-Bevacizumab PET: Potential Early Indicator of Everolimus Efficacy in Patients with Metastatic Renal Cell Carcinoma. <i>Journal of Nuclear Medicine</i> , 2017, 58, 905-910.	5.0	50
156	Molecular Imaging in Cancer Drug Development. <i>Journal of Nuclear Medicine</i> , 2018, 59, 726-732.	5.0	50
157	Potential Red-Flag Identification of Colorectal Adenomas with Wide-Field Fluorescence Molecular Endoscopy. <i>Theranostics</i> , 2018, 8, 1458-1467.	10.0	49
158	Enhanced Antitumor Efficacy of a DR5-Specific TRAIL Variant over Recombinant Human TRAIL in a Bioluminescent Ovarian Cancer Xenograft Model. <i>Clinical Cancer Research</i> , 2009, 15, 2048-2057.	7.0	48
159	Cancer-drug induced insulin resistance: Innocent bystander or unusual suspect. <i>Cancer Treatment Reviews</i> , 2015, 41, 376-384.	7.7	48
160	Positron emission tomography of tumour [¹⁸ F]fluoroestradiol uptake in patients with acquired hormone-resistant metastatic breast cancer prior to oestradiol therapy. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2015, 42, 1674-1681.	6.4	48
161	Androgen and Estrogen Receptor Imaging in Metastatic Breast Cancer Patients as a Surrogate for Tissue Biopsies. <i>Journal of Nuclear Medicine</i> , 2017, 58, 1906-1912.	5.0	48
162	Development, preclinical safety, formulation, and stability of clinical grade bevacizumab-800CW, a new near infrared fluorescent imaging agent for first in human use. <i>European Journal of Pharmaceutics and Biopharmaceutics</i> , 2016, 104, 226-234.	4.3	47

#	ARTICLE	IF	CITATIONS
163	New positron emission tomography tracer [¹¹ C]carvedilol reveals P-glycoprotein modulation kinetics. <i>British Journal of Pharmacology</i> , 2005, 145, 1045-1051.	5.4	46
164	ImmunopET and biodistribution with human epidermal growth factor receptor 3 targeting antibody ^{<sup>89</sup>Zr-RG7116. <i>MAbs</i>, 2014, 6, 1051-1058.}	5.2	46
165	Comparative biodistribution analysis across four different ^{<sup>89</sup>Zr-monoclonal antibody tracers}	10.0	46
166	”The first step towards an imaging warehouse. <i>Theranostics</i> , 2018, 8, 4295-4304.		
166	Irritability Rather Than Depression During Interferon Treatment Is Linked to Increased Tryptophan Catabolism. <i>Psychosomatic Medicine</i> , 2005, 67, 773-777.	2.0	45
167	^{<sup>18</sup>F-Fluoroestradiol Tumor Uptake Is Heterogeneous and Influenced by Site of Metastasis in Breast Cancer Patients. <i>Journal of Nuclear Medicine</i>, 2018, 59, 1212-1218.}	5.0	45
168	Calculating optimal surveillance for detection of von Hippel–Lindau-related manifestations. <i>Endocrine-Related Cancer</i> , 2014, 21, 63-71.	3.1	44
169	Assessment of Estrogen Receptor Expression in Epithelial Ovarian Cancer Patients Using ¹⁶ ±- ^{<sup>18</sup>F-Fluoro-17β-Estradiol PET/CT. <i>Journal of Nuclear Medicine</i>, 2015, 56, 50-55.}	5.0	44
170	Cigarette smoke extract affects functional activity of MRP1 in bronchial epithelial cells. <i>Journal of Biochemical and Molecular Toxicology</i> , 2007, 21, 243-251.	3.0	43
171	The extrinsic apoptosis pathway and its prognostic impact in ovarian cancer. <i>Gynecologic Oncology</i> , 2010, 116, 549-555.	1.4	43
172	Hormone receptors as a marker of poor survival in epithelial ovarian cancer. <i>Gynecologic Oncology</i> , 2015, 138, 634-639.	1.4	43
173	Imaging Diagnostic and Therapeutic Targets: Human Epidermal Growth Factor Receptor 2. <i>Journal of Nuclear Medicine</i> , 2016, 57, 81S-88S.	5.0	43
174	Web-Based Tailored Psychoeducation for Breast Cancer Patients at the Onset of the Survivorship Phase: AAMulticenter Randomized Controlled Trial. <i>Journal of Pain and Symptom Management</i> , 2017, 54, 466-475.	1.2	43
175	The role of breast cancer resistance protein in acute lymphoblastic leukemia. <i>Clinical Cancer Research</i> , 2003, 9, 5171-7.	7.0	43
176	Metastasis in soft tissue sarcomas: prognostic criteria and treatment perspectives. <i>Cancer and Metastasis Reviews</i> , 2002, 21, 167-183.	5.9	42
177	Complications of Midgut Carcinoid Tumors and Carcinoid Syndrome. <i>Neuroendocrinology</i> , 2004, 80, 28-32.	2.5	42
178	Higher levels of interleukin-6 in cystic fluids from patients with malignant versus benign ovarian tumors correlate with decreased hemoglobin levels and increased platelet counts. <i>Cancer</i> , 1995, 75, 1004-1009.	4.1	41
179	Detection of micrometastatic breast cancer by means of real time quantitative RT-PCR and immunostaining in perioperative blood samples and sentinel nodes. <i>International Journal of Cancer</i> , 2003, 106, 611-618.	5.1	41
180	Total 18F-dopa PET tumour uptake reflects metabolic endocrine tumour activity in patients with a carcinoid tumour. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2011, 38, 1854-1861.	6.4	41

#	ARTICLE	IF	CITATIONS
181	Longitudinal changes in cardiac function after cisplatin-based chemotherapy for testicular cancer. <i>Annals of Oncology</i> , 2011, 22, 2286-2293.	1.2	41
182	Clinical potential of inhibitors of survival pathways and activators of apoptotic pathways in treatment of cervical cancer: changing the apoptotic balance. <i>Lancet Oncology</i> , The, 2005, 6, 589-598.	10.7	40
183	Urinary 5-HIAA measurement using automated on-line solid-phase extractionâ€“high-performance liquid chromatographyâ€“tandem mass spectrometry. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2008, 868, 28-33.	2.3	40
184	Lapatinib and 17AAG Reduce ⁸⁹ Zr-Trastuzumab-F(abâ€²) ₂ Uptake in SKBR3 Tumor Xenografts. <i>Molecular Pharmaceutics</i> , 2012, 9, 2995-3002.	4.6	40
185	In Vivo Visualization of MET Tumor Expression and Anticalin Biodistribution with the MET-Specific Anticalin ⁸⁹ Zr-PRS-110 PET Tracer. <i>Journal of Nuclear Medicine</i> , 2014, 55, 665-671.	5.0	40
186	The antibodyâ€“drug conjugate target landscape across a broad range of tumour types. <i>Annals of Oncology</i> , 2017, 28, 3083-3091.	1.2	40
187	Phase I and Pharmacologic Study of Liposomal Lurtotecan, NX 211: Urinary Excretion Predicts Hematologic Toxicity. <i>Journal of Clinical Oncology</i> , 2002, 20, 1222-1231.	1.6	39
188	Predicting Early Failure after Adjuvant Chemotherapy in High-Risk Breast Cancer Patients with Extensive Lymph Node Involvement. <i>Clinical Cancer Research</i> , 2004, 10, 4457-4463.	7.0	39
189	Low p21Waf1/Cip1 protein level sensitizes testicular germ cell tumor cells to Fas-mediated apoptosis. <i>Oncogene</i> , 2004, 23, 4862-4872.	5.9	39
190	The Prognostic Effect of the Number of Histologically Examined Axillary Lymph Nodes in Breast Cancer: Stage Migration or Age Association?. <i>Annals of Surgical Oncology</i> , 2006, 13, 465-474.	1.5	39
191	¹¹¹ In-Trastuzumab Scintigraphy in HER2-Positive Metastatic Breast Cancer Patients Remains Feasible during Trastuzumab Treatment. <i>Molecular Imaging</i> , 2014, 13, 7290.2014.00011.	1.4	39
192	Niacin (Vitamin B₃) Supplementation in Patients with Serotonin-Producing Neuroendocrine Tumor. <i>Neuroendocrinology</i> , 2016, 103, 489-494.	2.5	39
193	Human Epidermal Growth Factor Receptor 3â€“Specific Tumor Uptake and Biodistribution of ⁸⁹ Zr-MSB0010853 Visualized by Real-Time and Noninvasive PET Imaging. <i>Journal of Nuclear Medicine</i> , 2017, 58, 1210-1215.	5.0	39
194	Knowledge and use of biosimilars in oncology: a survey by the European Society for Medical Oncology. <i>ESMO Open</i> , 2019, 4, e000460.	4.5	39
195	High Functional P-glycoprotein Activity is More Often Present in T-cell Acute Lymphoblastic Leukaemic Cells in Adults than in Children. <i>Leukemia and Lymphoma</i> , 2003, 44, 85-95.	1.3	38
196	Sensitivity to Fas-mediated apoptosis in high-risk HPV-positive human cervical cancer cells: Relationship with Fas, caspase-8, and Bid. <i>Gynecologic Oncology</i> , 2005, 97, 353-364.	1.4	38
197	Differential effects of all-trans -retinoic acid, docosahexaenoic acid, and hexadecylphosphocholine on cisplatin-induced cytotoxicity and apoptosis in a cisplatin-sensitive and resistant human embryonal carcinoma cell line. <i>Cancer Chemotherapy and Pharmacology</i> , 1998, 41, 469-476.	2.3	37
198	The HLA class III subregion is responsible for an increased breast cancer risk. <i>Human Molecular Genetics</i> , 2003, 12, 2311-2319.	2.9	37

#	ARTICLE	IF	CITATIONS
199	Molecular Imaging of PD-L1 Expression and Dynamics with the Adnectin-Based PET Tracer ¹⁸ F-BMS-986192. Journal of Nuclear Medicine, 2020, 61, 1839-1844.	5.0	37
200	Growth Differentiation Factor 15 (GDF-15) Plasma Levels Increase during Bleomycin- and Cisplatin-Based Treatment of Testicular Cancer Patients and Relate to Endothelial Damage. PLoS ONE, 2015, 10, e0115372.	2.5	37
201	Heat-shock protein expression in cisplatin-sensitive and -resistant human tumor cells. , 1996, 67, 800-807.		36
202	A Simple and Sensitive Fully Validated HPLC-UV Method for the Determination of 5-Fluorouracil and Its Metabolite 5,6-Dihydrofluorouracil in Plasma. Therapeutic Drug Monitoring, 2005, 27, 25-30.	2.0	36
203	Methylenetetrahydrofolate reductase (MTHFR) and susceptibility for (pre)neoplastic cervical disease. Human Genetics, 2005, 116, 247-254.	3.8	36
204	Targeting TRAIL death receptors. Current Opinion in Pharmacology, 2008, 8, 433-439.	3.5	36
205	Drug-induced caspase 8 upregulation sensitises cisplatin-resistant ovarian carcinoma cells to rhTRAIL-induced apoptosis. British Journal of Cancer, 2011, 104, 1278-1287.	6.4	36
206	Human Papilloma Virus 16 E6 RNA Interference Enhances Cisplatin and Death Receptor-Mediated Apoptosis in Human Cervical Carcinoma Cells. Molecular Pharmacology, 2012, 81, 701-709.	2.3	36
207	Molecular imaging to enlighten cancer immunotherapies and underlying involved processes. Cancer Treatment Reviews, 2018, 70, 232-244.	7.7	36
208	Breast Cancer Resistance Protein (BCRP) in Acute Leukaemia. Leukemia and Lymphoma, 2004, 45, 649-654.	1.3	35
209	The role of ATM and 53BP1 as predictive markers in cervical cancer. International Journal of Cancer, 2012, 131, 2056-2066.	5.1	35
210	Transforming growth factor (TGF)- β 2 expression and activation mechanisms as potential targets for anti-tumor therapy and tumor imaging. , 2012, 135, 123-132.		35
211	Nutlin-3 preferentially sensitises wild-type p53-expressing cancer cells to DR5-selective TRAIL over rhTRAIL. British Journal of Cancer, 2013, 109, 2685-2695.	6.4	35
212	CXCR4 inhibition enhances radiosensitivity, while inducing cancer cell mobilization in a prostate cancer mouse model. Clinical and Experimental Metastasis, 2014, 31, 829-839.	3.3	35
213	Safety, pharmacokinetics, and pharmacodynamics of the DR5 antibody LBY135 alone and in combination with capecitabine in patients with advanced solid tumors. Investigational New Drugs, 2014, 32, 135-144.	2.6	35
214	Serotonin and Dopamine Receptor Expression in Solid Tumours Including Rare Cancers. Pathology and Oncology Research, 2020, 26, 1539-1547.	1.9	35
215	Probody Therapeutic Design of ⁸⁹ Zr-CX-072 Promotes Accumulation in PD-L1-Expressing Tumors Compared to Normal Murine Lymphoid Tissue. Clinical Cancer Research, 2020, 26, 3999-4009.	7.0	35
216	Threshold Analysis and Biodistribution of Fluorescently Labeled Bevacizumab in Human Breast Cancer. Cancer Research, 2017, 77, 623-631.	0.9	34

#	ARTICLE	IF	CITATIONS
217	89Zr-labeled Bispecific T-cell Engager AMG 211 PET Shows AMG 211 Accumulation in CD3-rich Tissues and Clear, Heterogeneous Tumor Uptake. <i>Clinical Cancer Research</i> , 2019, 25, 3517-3527.	7.0	34
218	Microparticles from tumors exposed to radiation promote immune evasion in part by PD-L1. <i>Oncogene</i> , 2020, 39, 187-203.	5.9	34
219	⁸⁹ Zr-pembrolizumab biodistribution is influenced by PD-1-mediated uptake in lymphoid organs. , 2020, 8, e000938.		34
220	Routine bone scintigraphy in primary staging of soft tissue sarcoma. <i>Cancer</i> , 2000, 89, 1726-1731.	4.1	33
221	Selective expression of cholesterol metabolism genes in normal CD34+CD38 ⁺ cells with a heterogeneous expression pattern in AML cells. <i>Experimental Hematology</i> , 2006, 34, 622-630.	0.4	32
222	Immunoscintigraphy as Potential Tool in the Clinical Evaluation of HER2/neu Targeted Therapy. <i>Current Pharmaceutical Design</i> , 2008, 14, 3348-3362.	1.9	32
223	Zirconium-89-Trastuzumab Positron Emission Tomography As a Tool to Solve a Clinical Dilemma in a Patient With Breast Cancer. <i>Journal of Clinical Oncology</i> , 2012, 30, e74-e75.	1.6	32
224	HIF-1 α Overexpression in Ductal Carcinoma In Situ of the Breast in BRCA1 and BRCA2 Mutation Carriers. <i>PLoS ONE</i> , 2013, 8, e56055.	2.5	32
225	The components of progression as explanatory variables for overall survival in the Response Evaluation Criteria in Solid Tumours 1.1 database. <i>European Journal of Cancer</i> , 2014, 50, 1847-1853.	2.8	32
226	Micro-computed tomography (micro-CT) for intraoperative surgical margin assessment of breast cancer: A feasibility study in breast conserving surgery. <i>European Journal of Surgical Oncology</i> , 2018, 44, 1708-1713.	1.0	32
227	<i>RAS</i> and <i>BRAF</i> mutations in cell-free DNA are predictive for outcome of cetuximab monotherapy in patients with tissue-tested <i>RAS</i> wild-type advanced colorectal cancer. <i>Molecular Oncology</i> , 2019, 13, 2361-2374.	4.6	32
228	Development and Evaluation of Interleukin-2 α -Derived Radiotracers for PET Imaging of T Cells in Mice. <i>Journal of Nuclear Medicine</i> , 2020, 61, 1355-1360.	5.0	32
229	Patients With Carcinoid Syndrome Exhibit Symptoms of Aggressive Impulse Dysregulation. <i>Psychosomatic Medicine</i> , 2004, 66, 422-425.	2.0	32
230	Determination of Epirubicin and Its Metabolite Epirubicinol in Saliva and Plasma by HPLC. <i>Therapeutic Drug Monitoring</i> , 2003, 25, 433-440.	2.0	31
231	Automated On-Line Solid-Phase Extraction Coupled with HPLC for Measurement of 5-Hydroxyindole-3-acetic Acid in Urine. <i>Clinical Chemistry</i> , 2005, 51, 1698-1703.	3.2	31
232	Combining Simvastatin with the Farnesyltransferase Inhibitor Tipifarnib Results in an Enhanced Cytotoxic Effect in a Subset of Primary CD34+ Acute Myeloid Leukemia Samples. <i>Clinical Cancer Research</i> , 2009, 15, 3076-3083.	7.0	31
233	Imaging the distribution of an antibody-drug conjugate constituent targeting mesothelin with ⁸⁹ Zr and IRDye 800CW in mice bearing human pancreatic tumor xenografts. <i>Oncotarget</i> , 2015, 6, 42081-42090.	1.8	31
234	Biodistribution and PET Imaging of Labeled Bispecific T Cell α -Engaging Antibody Targeting EpCAM. <i>Journal of Nuclear Medicine</i> , 2016, 57, 812-817.	5.0	31

#	ARTICLE	IF	CITATIONS
235	Pharmacokinetics of gemcitabine in non-small-cell lung cancer patients: impact of the 79A>C cytidine deaminase polymorphism. <i>European Journal of Clinical Pharmacology</i> , 2010, 66, 611-617.	1.9	30
236	Pro- and anti-apoptotic effects of p53 in cisplatin-treated human testicular cancer are cell context-dependent. <i>Cell Cycle</i> , 2012, 11, 4552-4562.	2.6	30
237	Glypican 3 Overexpression across a Broad Spectrum of Tumor Types Discovered with Functional Genomic mRNA Profiling of a Large Cancer Database. <i>American Journal of Pathology</i> , 2018, 188, 1973-1981.	3.8	30
238	Lack of cross-resistance to fostriecin in a human small-cell lung carcinoma cell line showing topoisomerase II-related drug resistance. <i>Cancer Chemotherapy and Pharmacology</i> , 1991, 28, 461-464.	2.3	29
239	Cardiotoxicity associated with the use of trastuzumab in breast cancer patients. <i>Expert Review of Anticancer Therapy</i> , 2007, 7, 1763-1771.	2.4	28
240	Targeting FLIP and Mcl-1 using a combination of aspirin and sorafenib sensitizes colon cancer cells to TRAIL. <i>Journal of Pathology</i> , 2013, 229, 410-421.	4.5	28
241	Colorectal cancer and the CHEK2 1100delC mutation. <i>Genes Chromosomes and Cancer</i> , 2005, 43, 377-382.	2.8	27
242	TRAIL Induces Apoptosis in Human Colorectal Adenoma Cell Lines and Human Colorectal Adenomas. <i>Clinical Cancer Research</i> , 2006, 12, 4350-4356.	7.0	27
243	The chemokine network, a newly discovered target in high grade gliomas. <i>Critical Reviews in Oncology/Hematology</i> , 2011, 79, 154-163.	4.4	27
244	Molecular Imaging As a Tool for Drug Development and Trial Design. <i>Journal of Clinical Oncology</i> , 2015, 33, 2585-2587.	1.6	27
245	A phase 1b study evaluating the effect of elacestrant treatment on estrogen receptor availability and estradiol binding to the estrogen receptor in metastatic breast cancer lesions using 18F-FES PET/CT imaging. <i>Breast Cancer Research</i> , 2020, 22, 97.	5.0	27
246	Prospective Study of Long-Term Impact of Adjuvant High-Dose and Conventional-Dose Chemotherapy on Health-Related Quality of Life. <i>Journal of Clinical Oncology</i> , 2007, 25, 5403-5409.	1.6	26
247	The Prognostic Value of TRAIL and its Death Receptors in Cervical Cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2009, 75, 203-211.	0.8	26
248	Words Matter: Distinguishing "Personalized Medicine" and "Biologically Personalized Therapeutics". <i>Journal of the National Cancer Institute</i> , 2014, 106, dju321-dju321.	6.3	26
249	89Zr-Onartuzumab PET imaging of c-MET receptor dynamics. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2017, 44, 1328-1336.	6.4	26
250	CX-072 (pacmilimab), a Probody PD-L1 inhibitor, in advanced or recurrent solid tumors (PROCLAIM-CX-072): an open-label dose-finding and first-in-human study. , 2021, 9, e002447.		26
251	Differential regulation of IL-6 promoter activity in a human ovarian-tumor cell line transfected with various p53 mutants: Involvement of AP-1. , 1999, 81, 236-242.		25
252	Dispelling the myths around cancer care delivery: It's not all about costs. <i>Journal of Cancer Policy</i> , 2014, 2, 22-29.	1.4	25

#	ARTICLE	IF	CITATIONS
253	Sulfonylurea derivatives and cancer, friend or foe?. European Journal of Pharmacology, 2019, 861, 172598.	3.5	25
254	Modeling of Cisplatin-Induced Signaling Dynamics in Triple-Negative Breast Cancer Cells Reveals Mediators of Sensitivity. Cell Reports, 2019, 28, 2345-2357.e5.	6.4	25
255	Fluorescent image-guided surgery in breast cancer by intravenous application of a quenched fluorescence activity-based probe for cysteine cathepsins in a syngeneic mouse model. EJNMMI Research, 2020, 10, 111.	2.5	24
256	ENDOTOXIN INCREASES PLASMA SOLUBLE TUMOR NECROSIS FACTOR-RELATED APOPTOSIS-INDUCING LIGAND LEVEL MEDIATED BY THE p38 MITOGEN-ACTIVATED PROTEIN KINASE SIGNALING PATHWAY. Shock, 2004, 22, 186-188.	2.1	23
257	The analysis of longitudinal quality of life measures with informative drop-out: a pattern mixture approach. Quality of Life Research, 2010, 19, 137-148.	3.1	23
258	ADCC responses and blocking of EGFR-mediated signaling and cell growth by combining the anti-EGFR antibodies Imgatuzumab and cetuximab in NSCLC cells. Oncotarget, 2017, 8, 45432-45446.	1.8	23
259	Immune Modulation Therapy and Imaging: Workshop Report. Journal of Nuclear Medicine, 2018, 59, 410-417.	5.0	23
260	Molecular Imaging of Radiolabeled Bispecific T-Cell Engager 89Zr-AMG211 Targeting CEA-Positive Tumors. Clinical Cancer Research, 2018, 24, 4988-4996.	7.0	23
261	Interleukin-2 PET imaging in patients with metastatic melanoma before and during immune checkpoint inhibitor therapy. European Journal of Nuclear Medicine and Molecular Imaging, 2021, 48, 4369-4376.	6.4	23
262	Phase I Trial with BMS-275183, a Novel Oral Taxane with Promising Antitumor Activity. Clinical Cancer Research, 2006, 12, 1760-1767.	7.0	22
263	Targeting Pro-Apoptotic TRAIL Receptors Sensitizes HeLa Cervical Cancer Cells to Irradiation-Induced Apoptosis. International Journal of Radiation Oncology Biology Physics, 2008, 72, 543-552.	0.8	22
264	Haptoglobin phenotype is not a predictor of recurrence free survival in high-risk primary breast cancer patients. BMC Cancer, 2008, 8, 389.	2.6	22
265	A bioinformatical and functional approach to identify novel strategies for chemoprevention of colorectal cancer. Oncogene, 2011, 30, 2026-2036.	5.9	22
266	Inhibition of formyl peptide receptor in high-grade astrocytoma by Chemotaxis Inhibitory Protein of S. aureus. British Journal of Cancer, 2013, 108, 587-596.	6.4	22
267	Functional Genomic mRNA Profiling of a large cancer data base demonstrates mesothelin overexpression in a broad range of tumor types. Oncotarget, 2015, 6, 28164-28172.	1.8	22
268	One year growth hormone replacement therapy does not alter colonic epithelial cell proliferation in growth hormone deficient adults. Clinical Endocrinology, 2000, 52, 457-462.	2.4	21
269	Elevated hTERT mRNA levels: A potential determinant of bronchial squamous cell carcinoma (<i>in) Tj ETQq1 1 0.784314 rgBT ₂₁ /Overlock	5.1	21
270	Targeting Trail Towards the Clinic. Current Drug Targets, 2011, 12, 2079-2090.	2.1	21

#	ARTICLE	IF	CITATIONS
271	Toward Molecular Imagingâ€“Driven Drug Development in Oncology. <i>Cancer Discovery</i> , 2011, 1, 25-28.	9.4	21
272	Serial FLT PET imaging to discriminate between true progression and pseudoprogression in patients with newly diagnosed glioblastoma: a long-term follow-up study. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2018, 45, 2404-2412.	6.4	21
273	Clinical Validity of ^{16}F -Fluoro- ^{17}F -Estradiol Positron Emission Tomography/Computed Tomography to Assess Estrogen Receptor Status in Newly Diagnosed Metastatic Breast Cancer. <i>Journal of Clinical Oncology</i> , 2022, 40, 3642-3652.	1.6	21
274	Multiple VEGF Family Members are Simultaneously Expressed in Ovarian Cancer: a Proposed Model for Bevacizumab Resistance. <i>Current Pharmaceutical Design</i> , 2012, 18, 3784-3792.	1.9	20
275	^{89}Zr -mAb3481 PET for HER3 tumor status assessment during lapatinib treatment. <i>MAbs</i> , 2017, 9, 1370-1378.	5.2	20
276	Detailed statistical assessment of the characteristics of the ESMO Magnitude of Clinical Benefit Scale (ESMO-MCBS) threshold rules. <i>ESMO Open</i> , 2017, 2, e000216.	4.5	20
277	Decalcification of Breast Cancer Bone Metastases With EDTA Does Not Affect ER, PR, and HER2 Results. <i>American Journal of Surgical Pathology</i> , 2019, 43, 1355-1360.	3.7	20
278	Improving gene function predictions using independent transcriptional components. <i>Nature Communications</i> , 2021, 12, 1464.	12.8	20
279	Circulating apoptotic proteins are increased in long-term disease-free breast cancer survivors. <i>Acta Oncologica</i> , 2006, 45, 175-183.	1.8	19
280	Sexual Function in Patients with Metastatic Midgut Carcinoid Tumours. <i>Neuroendocrinology</i> , 2009, 89, 231-236.	2.5	19
281	Synthesis and Evaluation of the Estrogen Receptor ^{125}I -Selective Radioligand 2- ^{18}F -Fluoro-6-(6-Hydroxynaphthalen-2-yl)Pyridin-3-ol: Comparison with ^{16}F -Fluoro- ^{17}F -Estradiol. <i>Journal of Nuclear Medicine</i> , 2017, 58, 554-559.	5.0	19
282	First-in-Human Study of the Biodistribution and Pharmacokinetics of ^{89}Zr -CX-072, a Novel Immunopet Tracer Based on an Antiâ€“PD-L1 Probody. <i>Clinical Cancer Research</i> , 2021, 27, 5325-5333.	7.0	19
283	The value of PET/CT with FES or FDG tracers in metastatic breast cancer: a computer simulation study in ER-positive patients. <i>British Journal of Cancer</i> , 2015, 112, 1617-1625.	6.4	18
284	Mapping heterogeneity in glucose uptake in metastatic melanoma using quantitative ^{18}F -FDG PET/CT analysis. <i>EJNMMI Research</i> , 2018, 8, 101.	2.5	18
285	PET/CT Imaging of ^{89}Zr -N-sucDf-Pembrolizumab in Healthy Cynomolgus Monkeys. <i>Molecular Imaging and Biology</i> , 2021, 23, 250-259.	2.6	18
286	Current Treatment Strategies and Future Directions for Extrapulmonary Neuroendocrine Carcinomas. <i>JAMA Oncology</i> , 2021, 7, 759.	7.1	18
287	Immunogenicity after second and third mRNA-1273 vaccination doses in patients receiving chemotherapy, immunotherapy, or both for solid tumours. <i>Lancet Oncology</i> , The, 2022, 23, 833-835.	10.7	18
288	Renal dysfunction following high-dose carboplatin treatment. <i>Journal of Cancer Research and Clinical Oncology</i> , 1988, 114, 212-214.	2.5	17

#	ARTICLE	IF	CITATIONS
289	Calcium or Resistant Starch Does Not Affect Colonic Epithelial Cell Proliferation Throughout the Colon in Adenoma Patients: A Randomized Controlled Trial. <i>Nutrition and Cancer</i> , 2002, 43, 31-38.	2.0	17
290	Myocardial Metastases of Carcinoid Visualized by ¹⁸ F-Dihydroxy-Phenyl-Alanine Positron Emission Tomography. <i>Circulation</i> , 2008, 118, 1602-1604.	1.6	17
291	Immunotherapeutic options on the horizon in breast cancer treatment. , 2015, 156, 90-101.		17
292	⁸⁹ Zr-Bevacizumab PET Visualizes Disease Manifestations in Patients with von Hippel-Lindau Disease. <i>Journal of Nuclear Medicine</i> , 2016, 57, 1244-1250.	5.0	17
293	High-Dose Chemotherapy With Hematopoietic Stem Cell Transplant in Patients With High-Risk Breast Cancer and 4 or More Involved Axillary Lymph Nodes. <i>JAMA Oncology</i> , 2020, 6, 528.	7.1	17
294	Effect of novobiocin on cisplatin cytotoxicity and dna interstrand cross-link formation in a cisplatin-resistant, small-cell lung carcinoma cell line. <i>International Journal of Cancer</i> , 1993, 53, 110-117.	5.1	16
295	Telomerase targeting in cancer treatment: new developments. <i>Drug Resistance Updates</i> , 1999, 2, 104-115.	14.4	16
296	Pilot study of vaginal plethysmography in women treated with radiotherapy for gynecological cancer. <i>Gynecologic Oncology</i> , 2003, 91, 540-546.	1.4	16
297	Development of a radioiodinated apoptosis-inducing ligand, rhTRAIL, and a radiolabelled agonist TRAIL receptor antibody for clinical imaging studies. <i>British Journal of Pharmacology</i> , 2012, 165, 2203-2212.	5.4	16
298	Placental Growth Factor (PlGF)-Specific Uptake in Tumor Microenvironment of ⁸⁹ Zr-Labeled PlGF Antibody RO5323441. <i>Journal of Nuclear Medicine</i> , 2013, 54, 929-935.	5.0	16
299	Balancing treatment efficacy, toxicity and complication risk in elderly patients with metastatic renal cell carcinoma. <i>Cancer Treatment Reviews</i> , 2016, 46, 63-72.	7.7	16
300	Androgen receptor expression inversely correlates with immune cell infiltration in human epidermal growth factor receptor 2-positive breast cancer. <i>European Journal of Cancer</i> , 2018, 103, 52-60.	2.8	16
301	Quantitative Profiling of Platelet-Rich Plasma Indole Markers by Direct-Matrix Derivatization Combined with LC-MS/MS in Patients with Neuroendocrine Tumors. <i>Clinical Chemistry</i> , 2019, 65, 1388-1396.	3.2	16
302	Assessing population diversity in phase III trials of cancer drugs supporting Food and Drug Administration approval in solid tumors. <i>International Journal of Cancer</i> , 2021, 149, 1455-1462.	5.1	16
303	Extracellular domain shedding influences specific tumor uptake and organ distribution of the EGFR PET tracer ⁸⁹ Zr-imgatuzumab. <i>Oncotarget</i> , 2016, 7, 68111-68121.	1.8	16
304	HLA-Dr-expressing CD8bright cells are only temporarily present in the circulation during subcutaneous recombinant interleukin-2 therapy in renal cell carcinoma patients. <i>Cancer Immunology, Immunotherapy</i> , 1993, 36, 198-204.	4.2	15
305	No association between two MLH3 variants (S845G and P844L) and colorectal cancer risk. <i>Cancer Genetics and Cytogenetics</i> , 2004, 152, 70-71.	1.0	15
306	A robust <i>ex vivo</i> model for evaluation of induction of apoptosis by rhTRAIL in combination with proteasome inhibitor MG132 in human premalignant cervical explants. <i>International Journal of Cancer</i> , 2008, 123, 1457-1465.	5.1	15

#	ARTICLE	IF	CITATIONS
307	Elevated Urinary Free and Deconjugated Catecholamines after Consumption of a Catecholamine-Rich Diet. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2010, 95, 2851-2855.	3.6	15
308	Treatment with high-dose simvastatin inhibits geranylgeranylation in AML blast cells in a subset of AML patients. <i>Experimental Hematology</i> , 2012, 40, 177-186.e6.	0.4	15
309	Visualising dual downregulation of insulin-like growth factor receptor-1 and vascular endothelial growth factor-A by heat shock protein 90 inhibition effect in triple negative breast cancer. <i>European Journal of Cancer</i> , 2014, 50, 2508-2516.	2.8	15
310	Clinical-grade N-(4-[18F]fluorobenzoyl)-interleukin-2 for PET imaging of activated T-cells in humans. <i>EJNMMI Radiopharmacy and Chemistry</i> , 2019, 4, 15.	3.9	15
311	CXCR4 and CXCL12 Expression in Rectal Tumors of Stage IV Patients Before and After Local Radiotherapy and Systemic Neoadjuvant Treatment. <i>Current Pharmaceutical Design</i> , 2015, 21, 2276-2283.	1.9	15
312	Abdominal Angina in Patients with a Midgut Carcinoid, a Sign of Severe Pathology. <i>World Journal of Surgery</i> , 2005, 29, 1139-1142.	1.6	14
313	Variability in responsiveness to lovastatin of the primitive CD34+ AML subfraction compared to normal CD34+ cells. <i>Annals of Hematology</i> , 2009, 88, 573-580.	1.8	14
314	Heterogeneity in simvastatin-induced cytotoxicity in AML is caused by differences in Ras-isoprenylation. <i>Leukemia</i> , 2012, 26, 845-848.	7.2	14
315	Molecular imaging for monitoring treatment response in breast cancer patients. <i>European Journal of Pharmacology</i> , 2013, 717, 2-11.	3.5	14
316	Molecular imaging in lymphoma beyond 18F-FDG-PET: understanding the biology and its implications for diagnostics and therapy. <i>Lancet Haematology</i> , 2020, 7, e479-e489.	4.6	14
317	Considering the biology of late recurrences in selecting patients for extended endocrine therapy in breast cancer. <i>Cancer Treatment Reviews</i> , 2018, 70, 118-126.	7.7	13
318	Neuroendocrine tumours and their microenvironment. <i>Cancer Immunology, Immunotherapy</i> , 2020, 69, 1449-1459.	4.2	13
319	Visual and quantitative evaluation of [18F]FES and [18F]FDHT PET in patients with metastatic breast cancer: an interobserver variability study. <i>EJNMMI Research</i> , 2020, 10, 40.	2.5	13
320	PET/CT with 89Zr-trastuzumab and 18F-FDG to individualize treatment with trastuzumab emtansine (T-DM1) in metastatic HER2-positive breast cancer (mBC).. <i>Journal of Clinical Oncology</i> , 2014, 32, 11001-11001.	1.6	13
321	A patient education program for a continuous infusion regimen on an outpatient basis. <i>Cancer Nursing</i> , 1987, 10, 177-182.	1.5	12
322	A phase II study of carboplatin and vincristine in previously treated patients with small-cell lung cancer. <i>Cancer Chemotherapy and Pharmacology</i> , 1989, 25, 202-204.	2.3	12
323	Sensitization to cisplatin action by step-down heating in cddp-sensitive and -resistant cells. <i>International Journal of Cancer</i> , 1995, 61, 722-726.	5.1	12
324	Impact of intracellular chloride concentration on cisplatin accumulation in sensitive and resistant GLC4 cells. <i>Journal of Biological Inorganic Chemistry</i> , 2009, 14, 123-132.	2.6	12

#	ARTICLE	IF	CITATIONS
325	Improvements in small bowel carcinoid diagnosis and staging: 18F-DOPA PET, capsule endoscopy and double balloon enteroscopy. Digestive and Liver Disease, 2009, 41, e35-e38.	0.9	12
326	Objective allergy markers and risk of cancer mortality and hospitalization in a large population-based cohort. Cancer Causes and Control, 2015, 26, 99-109.	1.8	12
327	Harnessing Integrative Omics to Facilitate Molecular Imaging of the Human Epidermal Growth Factor Receptor Family for Precision Medicine. Theranostics, 2017, 7, 2111-2133.	10.0	12
328	Influence of protein properties and protein modification on biodistribution and tumor uptake of anticancer antibodies, antibody derivatives, and nonâ€lg scaffolds. Medicinal Research Reviews, 2018, 38, 1837-1873.	10.5	12
329	When is off-label off-road?. Annals of Oncology, 2019, 30, 1536-1538.	1.2	12
330	Assessment of Bone Lesions with ¹⁸ F-FDG PET Compared with ^{99m} Tc Bone Scintigraphy Leads to Clinically Relevant Differences in Metastatic Breast Cancer Management. Journal of Nuclear Medicine, 2021, 62, 177-183.	5.0	12
331	The role of local therapy in the treatment of solitary melanoma progression on immune checkpoint inhibition: A multicentre retrospective analysis. European Journal of Cancer, 2021, 151, 72-83.	2.8	12
332	Renal toxicity of the anticancer drug fostriecin. Cancer Chemotherapy and Pharmacology, 1998, 42, 160-164.	2.3	11
333	Beware of Amenorrhea During Tamoxifen: It May Be a Wolf in Sheep's Clothing. Journal of Clinical Oncology, 2007, 25, 3787-3788.	1.6	11
334	A New Perspective on Transcriptional System Regulation (TSR): Towards TSR Profiling. PLoS ONE, 2008, 3, e1656.	2.5	11
335	Analyzing longitudinal data with patients in different disease states during followâ€up and death as final state. Statistics in Medicine, 2009, 28, 3829-3843.	1.6	11
336	Perspectives for tailored chemoprevention and treatment of colorectal cancer in Lynch syndrome. Critical Reviews in Oncology/Hematology, 2011, 80, 264-277.	4.4	11
337	Bevacizumab-Induced Vessel Normalization Hampers Tumor Uptake of Antibodiesâ€™Response. Cancer Research, 2013, 73, 7147-7148.	0.9	11
338	Difference in CXCR4 expression between sporadic and VHL-related hemangioblastoma. Familial Cancer, 2016, 15, 607-616.	1.9	11
339	Interobserver reproducibility of tumor uptake quantification with 89Zr-immuno-PET: a multicenter analysis. European Journal of Nuclear Medicine and Molecular Imaging, 2019, 46, 1840-1849.	6.4	11
340	Quantitative proteomics analysis identifies MUC1 as an effect sensor of EGFR inhibition. Oncogene, 2019, 38, 1477-1488.	5.9	11
341	Impact of rituximab biosimilars on overall survival in diffuse large B-cell lymphoma: a Dutch population-based study. Blood Advances, 2021, 5, 2958-2964.	5.2	11
342	Stability of the new anticancer platinum analogue 1,2-diaminomethyl-cyclobutane-platinum(II)-lactate (lobaplatin; D19466) in intravenous solutions. Pharmaceutical Research, 1992, 09, 808-811.	3.5	10

#	ARTICLE	IF	CITATIONS
343	Evaluation of S9788 as a potential modulator of drug resistance against human tumour sublines expressing differing resistance mechanisms <i>In Vitro</i> . <i>International Journal of Cancer</i> , 1993, 55, 330-337.	5.1	10
344	Tumor progression in a giant cell type malignant fibrous histiocytoma of bone: Clinical, radiologic, histologic, and cytogenetic evidence. <i>Genes Chromosomes and Cancer</i> , 1994, 10, 66-70.	2.8	10
345	The dilemma of the strive for apoptosis in oncology: mind the heart. <i>Critical Reviews in Oncology/Hematology</i> , 2005, 53, 101-113.	4.4	10
346	Combining 6-fluoro-[18F]-dihydroxyphenylalanine and [18F]fluoro-2-deoxy-d-glucose positron emission tomography for distinction of non-carcinoid malignancies in carcinoid patients. <i>European Journal of Cancer</i> , 2009, 45, 2312-2315.	2.8	10
347	TNF α -related apoptosis-inducing ligand cooperates with NSAIDs via activated Wnt signalling in (pre)malignant colon cells. <i>Journal of Pathology</i> , 2011, 223, 378-389.	4.5	10
348	Vemurafenib-Induced Disseminated Intravascular Coagulation in Metastatic Melanoma. <i>Journal of Clinical Oncology</i> , 2015, 33, e133-e134.	1.6	10
349	A Phase Ib Study of the VEGF Receptor Tyrosine Kinase Inhibitor Tivozanib and Modified FOLFOX-6 in Patients With Advanced Gastrointestinal Malignancies. <i>Clinical Colorectal Cancer</i> , 2015, 14, 18-24.e1.	2.3	10
350	Potential value of EUS in pancreatic surveillance of VHL patients. <i>European Journal of Endocrinology</i> , 2016, 174, 611-620.	3.7	10
351	Which patients are prone to undergo disproportionate recurrent CT imaging and should we worry?. <i>European Journal of Radiology</i> , 2020, 125, 108898.	2.6	10
352	EHA evaluation of the ESMO α Magnitude of Clinical Benefit Scale version 1.1 (ESMO-MCBS v1.1) for haematological malignancies. <i>ESMO Open</i> , 2020, 5, e000611.	4.5	10
353	89 Zr-bevacizumab PET imaging in metastatic renal cell carcinoma patients before and during antiangiogenic treatment.. <i>Journal of Clinical Oncology</i> , 2012, 30, 10581-10581.	1.6	10
354	Continuous infusion of low-dose doxorubicin, epirubicin and mitoxantrone in cancer chemotherapy: A review. <i>Pharmaceutisch Weekblad</i> , 1988, 10, 237-245.	0.7	9
355	Extensive hepatic replacement due to liver metastases has no effect on 5-fluorouracil pharmacokinetics. <i>Cancer Chemotherapy and Pharmacology</i> , 2003, 51, 167-173.	2.3	9
356	Diagnostic 131 I scintigraphy in patients with differentiated thyroid cancer: No additional value of higher scan dose. <i>Annals of Nuclear Medicine</i> , 2004, 18, 641-6.	2.2	9
357	Total Abdominal 18F-FDG Uptake Reflects Intestinal Adenoma Burden in Apc Mutant Mice. <i>Journal of Nuclear Medicine</i> , 2011, 52, 431-436.	5.0	9
358	Tailored imaging of islet cell tumors of the pancreas amidst increasing options. <i>Critical Reviews in Oncology/Hematology</i> , 2012, 82, 213-226.	4.4	9
359	Microenvironment involved in FPR1 expression by human glioblastomas. <i>Journal of Neuro-Oncology</i> , 2015, 123, 53-63.	2.9	9
360	Bleomycin-Induced Pulmonary Changes on Restaging Computed Tomography Scans in Two Thirds of Testicular Cancer Patients Show No Correlation With Fibrosis Markers. <i>Oncologist</i> , 2016, 21, 995-1001.	3.7	9

#	ARTICLE	IF	CITATIONS
361	European Academy of Cancer Sciences â€“ position paper. <i>Molecular Oncology</i> , 2018, 12, 1829-1837.	4.6	9
362	The Biodistribution of a CD3 and EpCAM Bispecific T-Cell Engager Is Driven by the CD3 Arm. <i>Journal of Nuclear Medicine</i> , 2020, 61, 1594-1601.	5.0	9
363	Exploiting the Apoptotic Route for Cancer Treatment: A Single Hit Will Rarely Result in a Home Run. <i>Journal of Clinical Oncology</i> , 2008, 26, 5151-5153.	1.6	8
364	Fas Ligand Expression in Lynch Syndrome-Associated Colorectal Tumours. <i>Pathology and Oncology Research</i> , 2009, 15, 399-406.	1.9	8
365	Turning promise into progress for antiangiogenic agents in epithelial ovarian cancer. <i>Critical Reviews in Oncology/Hematology</i> , 2012, 84, 224-242.	4.4	8
366	Translation of New Molecular Imaging Approaches to the Clinical Setting: Bridging the Gap to Implementation. <i>Journal of Nuclear Medicine</i> , 2016, 57, 96S-104S.	5.0	8
367	Preparing for the incoming wave of biosimilars in oncology. <i>ESMO Open</i> , 2018, 3, e000420.	4.5	8
368	⁸⁹ Zr-GC1008 PET imaging and GC1008 treatment of recurrent glioma patients.. <i>Journal of Clinical Oncology</i> , 2013, 31, 2050-2050.	1.6	8
369	The Role of Apoptosis-Related Genes in nonâ€”small-Cell Lung Cancer. <i>Clinical Lung Cancer</i> , 2002, 4, 174-182.	2.6	7
370	S-Decyl-glutathione nonspecifically stimulates the ATPase activity of the nucleotide-binding domains of the human multidrug resistance-associated protein, MRP1 (ABCC1). <i>FEBS Journal</i> , 2002, 269, 3470-3478.	0.2	7
371	Quality of adjuvant CMF chemotherapy for node-positive primary breast cancer: a population-based study. <i>Journal of Cancer Research and Clinical Oncology</i> , 2004, 130, 581-590.	2.5	7
372	The Human Leukocyte Antigen Region and Colorectal Cancer Risk. <i>Diseases of the Colon and Rectum</i> , 2005, 48, 303-306.	1.3	7
373	Factors influencing catheter-related infections in the Dutch multicenter study on high-dose chemotherapy followed by peripheral SCT in high-risk breast cancer patients. <i>Bone Marrow Transplantation</i> , 2008, 42, 475-481.	2.4	7
374	Effect of vemurafenib on a V600R melanoma brain metastasis. <i>European Journal of Cancer</i> , 2013, 49, 1795-1796.	2.8	7
375	⁸⁹ Zr-labeled anti-PD-L1 CX-072 PET imaging in human xenograft and syngeneic tumors. <i>Annals of Oncology</i> , 2019, 30, i4.	1.2	7
376	Application of the ESMO-Magnitude of Clinical Benefit Scale (V.1.1) to the field of early breast cancer therapies. <i>ESMO Open</i> , 2020, 5, e000743.	4.5	7
377	High hepatocyte growth factor expression in primary tumor predicts better overall survival in male breast cancer. <i>Breast Cancer Research</i> , 2020, 22, 30.	5.0	7
378	Phase I imaging study of the HER3 antibody RG7116 using ⁸⁹ Zr-RG7116-PET in patients with metastatic or locally advanced HER3-positive solid tumors.. <i>Journal of Clinical Oncology</i> , 2014, 32, 11095-11095.	1.6	7

#	ARTICLE	IF	CITATIONS
379	Validation of RECIST 1.1 for use with cytotoxic agents and targeted cancer agents (TCA): Results of a RECIST Working Group analysis of a 50 clinical trials pooled individual patient database.. Journal of Clinical Oncology, 2017, 35, 2534-2534.	1.6	7
380	Life-prolonging treatment restrictions and outcomes in patients with cancer and COVID-19: an update from the Dutch Oncology COVID-19 Consortium. European Journal of Cancer, 2022, 160, 261-272.	2.8	7
381	5-fluorouracil/leucovorin/interferon alpha-2a in patients with advanced colorectal cancer. Effects of maintenance therapy on remission duration. Cancer, 1995, 75, 1072-1076.	4.1	6
382	Low plasma tryptophan in carcinoid patients is associated with increased urinary cortisol excretion. Psychoneuroendocrinology, 2008, 33, 1297-1301.	2.7	6
383	Everolimus Effect on Gastrin and Glucagon in Pancreatic Neuroendocrine Tumors. Pancreas, 2017, 46, 751-757.	1.1	6
384	In Vivo Quantification of ER ¹² Expression by Pharmacokinetic Modeling: Studies with ¹⁸ F-FHNP PET. Journal of Nuclear Medicine, 2017, 58, 1743-1748.	5.0	6
385	Design and Conduct of Early Clinical Studies of Immunotherapy: Recommendations from the Task Force on Methodology for the Development of Innovative Cancer Therapies 2019 (MDICT). Clinical Cancer Research, 2020, 26, 2461-2465.	7.0	6
386	Human stromal cells are required for an anti-breast cancer effect of zoledronic acid. Oncotarget, 2015, 6, 24436-24447.	1.8	6
387	TNO-6-induced acute renal failure. A case report. Cancer, 1985, 56, 1511-1514.	4.1	5
388	Intraperitoneal chemotherapy for ovarian cancer: a question of feasibility?. Drug Resistance Updates, 2003, 6, 165-167.	14.4	5
389	Hemodialysis no reason to withhold everolimus. Cancer Chemotherapy and Pharmacology, 2013, 71, 273-274.	2.3	5
390	Lessons learnt from scoring adjuvant colon cancer trials and meta-analyses using the ESMO-Magnitude of Clinical Benefit Scale V.1.1. ESMO Open, 2020, 5, e000681.	4.5	5
391	A phase I study of DMOT4039A, an antibody-drug conjugate (ADC) targeting mesothelin (MSLN), in patients (pts) with unresectable pancreatic (PC) or platinum-resistant ovarian cancer (OC).. Journal of Clinical Oncology, 2014, 32, 2529-2529.	1.6	5
392	Everolimus in patients with advanced, progressive pancreatic neuroendocrine tumors: Overall survival results from the phase III RADIANT-3 study after adjusting for crossover bias.. Journal of Clinical Oncology, 2015, 33, 4091-4091.	1.6	5
393	The relation between soluble apoptotic proteins and subclinical cardiotoxicity in adjuvant-treated breast cancer patients. Anticancer Research, 2006, 26, 3803-11.	1.1	5
394	Emerging Opportunities for c-MET Visualization in the Clinic. Journal of Nuclear Medicine, 2016, 57, 663-664.	5.0	4
395	Towards optimal personalized diet and vitamin supplementation in NET patients. Endocrine-Related Cancer, 2018, 25, L23-L26.	3.1	4
396	Shortages of inexpensive essential medicines. Lancet Oncology, The, 2019, 20, e224-e225.	10.7	4

#	ARTICLE	IF	CITATIONS
397	Visualizing Cancer. <i>Cancer Cell</i> , 2020, 38, 753-756.	16.8	4
398	Analyzing the Estrogen Receptor Status of Liver Metastases with [18F]-FES-PET in Patients with Breast Cancer. <i>Diagnostics</i> , 2021, 11, 2019.	2.6	4
399	Serotonin rising. <i>New England Journal of Medicine</i> , 2009, 360, 2580-1; author reply 2581-2.	27.0	4
400	Effect of ultrafilterable platinum concentration on cisplatin and carboplatin cytotoxicity in human tumor and bone marrow cells in vitro. <i>Pharmaceutical Research</i> , 1994, 11, 1265-1269.	3.5	3
401	Pancreatic Uptake by 18F-FDOPA PET/CT in Patients With Hypoglycemia After Gastric Bypass Surgery Compared With Controls With or Without Carbidopa Pretreatment. <i>Clinical Nuclear Medicine</i> , 2017, 42, 163-168.	1.3	3
402	Melatonin is not stored in platelets. <i>Clinica Chimica Acta</i> , 2019, 498, 17-20.	1.1	3
403	Interlesional Heterogeneity of Metastatic Neuroendocrine Tumors Based on 18F-DOPA PET/CT. <i>Clinical Nuclear Medicine</i> , 2019, 44, 612-619.	1.3	3
404	Mesothelin/CD3 half-life extended bispecific T-cell engager molecule shows specific tumor uptake and distributes to mesothelin and CD3 expressing tissues. <i>Journal of Nuclear Medicine</i> , 2021, , jnumed.120.259036.	5.0	3
405	Phase I study of AMG 211/MEDI-565 administered as continuous intravenous infusion for relapsed/refractory gastrointestinal (GI) adenocarcinoma.. <i>Journal of Clinical Oncology</i> , 2015, 33, TPS3097-TPS3097.	1.6	3
406	Noise sensitivity of 89Zr-Immuno-PET radiomics based on count-reduced clinical images. <i>EJNMMI Physics</i> , 2022, 9, 16.	2.7	3
407	Radiolabeled Monoclonal Antibody Against Colony-Stimulating Factor 1 Receptor Specifically Distributes to the Spleen and Liver in Immunocompetent Mice. <i>Frontiers in Oncology</i> , 2021, 11, 786191.	2.8	3
408	89Zr-PET imaging to predict tumor uptake of 177Lu-NNV003 anti-CD37 radioimmunotherapy in mouse models of B cell lymphoma. <i>Scientific Reports</i> , 2022, 12, 6286.	3.3	3
409	Gemcitabine and Epirubicin Plasma Concentration-Related Excretion in Saliva in Patients With Nonâ€Small Cell Lung Cancer. <i>Therapeutic Drug Monitoring</i> , 2010, 32, 364-368.	2.0	2
410	Video-rate optical flow corrected intraoperative functional fluorescence imaging. <i>Journal of Biomedical Optics</i> , 2014, 19, 1.	2.6	2
411	Indispensable benefit of independent investigator-driven research in a changing clinical trial landscape. <i>ESMO Open</i> , 2017, 2, e000272.	4.5	2
412	Use of Video-consultation is Feasible During Follow-up Care of Patients with a Neuroendocrine Tumour. <i>Clinical Oncology</i> , 2018, 30, 396.	1.4	2
413	ESMO-MCBS: setting the record straight. <i>Lancet Oncology</i> , The, 2019, 20, e192.	10.7	2
414	Driving innovation for rare skin cancers: utilizing common tumours and machine learning to predict immune checkpoint inhibitor response. <i>Immuno-Oncology Technology</i> , 2019, 4, 1-7.	0.3	2

#	ARTICLE	IF	CITATIONS
415	Reconsider radiation exposure from imaging during immune checkpoint inhibitor trials to reduce risk of secondary cancers in long-term survivors?. Cancer Treatment Reviews, 2020, 87, 102027.	7.7	2
416	The global imperative to make cancer medications affordable. Lancet Oncology, The, 2020, 21, 609-610.	10.7	2
417	Prospective analysis of serial FLT-PET scanning to discriminate between true and pseudoprogression in glioblastoma.. Journal of Clinical Oncology, 2014, 32, 2009-2009.	1.6	2
418	FES PET/CT analysis to evaluate the impact of localization of breast cancer metastases on ER expression.. Journal of Clinical Oncology, 2015, 33, 527-527.	1.6	2
419	Androgen receptor and estrogen receptor imaging in patients with metastatic breast cancer.. Journal of Clinical Oncology, 2016, 34, 11553-11553.	1.6	2
420	A Phase 1 study of RAD1901, an oral selective estrogen receptor degrader, in ER positive, HER2 negative, advanced breast cancer patients.. Journal of Clinical Oncology, 2016, 34, TPS627-TPS627.	1.6	2
421	Pharmacokinetics of cetuximab and tumor uptake of ⁸⁹ Zr-cetuximab as potential predictive biomarkers for benefit of cetuximab in patients with advanced colorectal cancer.. Journal of Clinical Oncology, 2017, 35, e15117-e15117.	1.6	2
422	Mass spectrometric quantification of urinary 6-sulfatoxymelatonin: age-dependent excretion and biological variation. Clinical Chemistry and Laboratory Medicine, 2021, 59, 187-195.	2.3	2
423	⁸⁹ Zr-3,2-HOPO-mesothelin antibody PET imaging reflects tumor uptake of mesothelin targeted ²²⁷ Th-conjugate therapy in mice. Journal of Nuclear Medicine, 2022, , jnumed.121.263079.	5.0	2
424	The gut wall's potential as a partner for precision oncology in immune checkpoint treatment. Cancer Treatment Reviews, 2022, 107, 102406.	7.7	2
425	Defining Essential Childhood Cancer Medicines to Inform Prioritization and Access: Results From an International, Cross-Sectional Survey. JCO Global Oncology, 2022, , .	1.8	2
426	Experimental animal model for anthracycline-induced heart failure. European Journal of Heart Failure, 2004, 6, 375-376.	7.1	1
427	Effect of interferon and 5-fluorouracil on serum VEGF levels in neuroendocrine tumours. Acta Oncologica, 2008, 47, 153-155.	1.8	1
428	Considerations on absence of ⁶⁸ Ga-DOTA-F(ab ²)-trastuzumab tracer uptake in HER2-overexpressing tumor lesions. Nuclear Medicine Communications, 2014, 35, 785-786.	1.1	1
429	Reply to the letter to the editor "Re-aligning the ASCO and ESMO clinical benefit frameworks or modern cancer therapies". Annals of Oncology, 2018, 29, 774-775.	1.2	1
430	Reply to the letter to the editor "Toxicity adjustment in the ESMO-MCBS: a Gestalt approach?" by Del Paggio. Annals of Oncology, 2018, 29, 521-522.	1.2	1
431	RE: Magnitude of Clinical Benefit of Cancer Drugs Approved by the US Food and Drug Administration. Journal of the National Cancer Institute, 2018, 110, 1142-1143.	6.3	1
432	Improving on Tail-of-the-Curve Evaluation With the American Society of Clinical Oncology Value Framework. JAMA Oncology, 2018, 4, 1437.	7.1	1

#	ARTICLE	IF	CITATIONS
433	Correcting the Conclusion in a Study of Frameworks for Measurement of Absolute or Relative Clinical Survival Benefit. JAMA Oncology, 2019, 5, 1807.	7.1	1
434	A Conversation Between Elisabeth de Vries and Johannes Czernin. Journal of Nuclear Medicine, 2019, 60, 1337-1339.	5.0	1
435	Molecular Imaging in Head and Neck Squamous Cell Carcinoma Patients. , 2017, , 77-96.		1
436	Prediction of watchful waiting in newly diagnosed metastatic clear cell renal cell carcinoma patients with a good or intermediate prognosis.. Journal of Clinical Oncology, 2020, 38, 5079-5079.	1.6	1
437	Letter to the Editor: When Expertly Applied, ESMO-MCBS and ASCO Net Health Benefit Scores Usually Agree. Journal of the National Comprehensive Cancer Network: JNCCN, 2019, 17, xxi.	4.9	1
438	PROCLAIM-CX-072: Analysis of patients with advanced solid tumors receiving long-term treatment with CX-072, a PD-L1 probody therapeutic, as a single agent or in combination with ipilimumab.. Journal of Clinical Oncology, 2020, 38, 3005-3005.	1.6	1
439	Reply to the letter to the editor â€œAddressing the quality of the ESMO-MCBSâ€™™ by Del Paggio. Annals of Oncology, 2017, 28, 2031-2032.	1.2	0
440	Reply to the letter to the editor â€œESMO-MCBS v1.1: statistical and patient relevant shortcomingsâ€™™ by Emrechtinger et al.. Annals of Oncology, 2018, 29, 1335-1338.	1.2	0
441	A large pooled analysis refines gene expression-based molecular subclasses in cutaneous melanoma. Oncoimmunology, 2019, 8, 1558664.	4.6	0
442	Measuring Clinical Benefit of Treatments for Hematologic Malignancies: Critical First Steps Accomplishedâ€™™What is Next?. HemaSphere, 2020, 4, e354.	2.7	0
443	The components of progression as explanatory variables for overall survival in the RECIST database.. Journal of Clinical Oncology, 2012, 30, 10602-10602.	1.6	0
444	Association of long-term exposure to circulating platinum with adverse late effects in testicular cancer survivors.. Journal of Clinical Oncology, 2012, 30, 4528-4528.	1.6	0
445	Macrophage inhibitory cytokine 1 plasma levels in testicular cancer patients during cisplatin combination treatment and their relation to endothelial damage.. Journal of Clinical Oncology, 2012, 30, e15035-e15035.	1.6	0
446	Residual estrogen receptor availability during fulvestrant 500 mg therapy in patients with metastatic breast cancer.. Journal of Clinical Oncology, 2014, 32, 588-588.	1.6	0
447	⁸⁹ Zr-bevacizumab PET imaging of disease manifestations in patients with Von Hippel-Lindau disease.. Journal of Clinical Oncology, 2014, 32, 11090-11090.	1.6	0
448	Bleomycin-induced pulmonary changes on restaging CT scans: Frequency and correlation with fibrosis markers.. Journal of Clinical Oncology, 2015, 33, 4540-4540.	1.6	0
449	⁸⁹ Zr-lumretuzumab PET imaging before and during HER3 antibody lumretuzumab treatment of solid tumor patients.. Journal of Clinical Oncology, 2016, 34, 11555-11555.	1.6	0
450	Change in metabolic tumor activity on ¹⁸ F-FDG PET after a single dose of cetuximab to predict for treatment benefit, PFS, and OS in patients with advanced colorectal cancer.. Journal of Clinical Oncology, 2017, 35, 11519-11519.	1.6	0

#	ARTICLE	IF	CITATIONS
451	The role of methoxymorpholino anthracycline and cyanomorpholino anthracycline in a sensitive small-cell lung-cancer cell line and its multidrug-resistant but P-glycoprotein-negative and cisplatin-resistant counterparts. <i>Cancer Chemotherapy and Pharmacology</i> , 1995, 35, 345-348.	2.3	0
452	Predictive value of ectopic <i>HORMAD1</i> tumor expression for high-dose platinum-based chemotherapy benefit in patients with high-risk HER2-negative breast cancer.. <i>Journal of Clinical Oncology</i> , 2022, 40, 541-541.	1.6	0